Discovers and develops new medicines for patients with rare disorders. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
Average growth of 34% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 39% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 34% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 49/100. For a turnaround signal, the stock first needs to close the gap with the market.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, PTCT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PTCT does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.